Altered gene expression profiles in stable versus acute childhood asthma
View Patent ↗Differences in gene expression in control and asthma patients to profile, differentiate, evaluate, etc. patients with exacerbated asthma and stable asthma.
1. A method to evaluate a patient, the method comprising
subjecting a tissue sample from a human patient with asthma to gene analysis, the analysis resulting in an expression profile of at least one gene activated in lungs of a human patient with asthma,
comparing the patient's gene expression profile with a gene expression profile for stable asthma and a gene expression profile for exacerbated asthma, and
determining whether the patient has a propensity for at least one of stable asthma or exacerbated asthma based on at least a two-fold difference between at least one gene in the patient's gene expression profile and the stable asthma or exacerbated asthma expression profile, wherein
the patient has a propensity for stable asthma when the at least two-fold difference is between the patient's gene expression profile and the gene expression profile for exacerbated asthma, or
the patient has a propensity for exacerbated asthma when the at least two-fold difference is between the patient's gene expression profile and the gene expression profile for stable asthma.
2. The method of claim 1 based on at least a three-fold difference.
3. The method of claim 1 wherein the tissue is nasal respiratory epithelium.
4. The method of claim 1 comparing a cluster of genes.
5. The method of claim 1 or claim 2 wherein the gene that has the difference between the patient's gene expression profile and the stable asthma gene expression profile is at least one of SEQ ID NOS: 11-14, 17, 20, 22-24, 26-27, 30, 32-34, 36, 39-47, 49-50, 52-57, 59-62, 65-70, 73-75, 78-84, 86, 88-94, 96-100, 103-112, 114-122, 124-125, 127-130, 133-145, 148-149, 153, 155-165, or 167, and the difference indicates a propensity for exacerbated asthma.
6. The method of claim 1 or claim 2 wherein the gene that has the difference between the patient's gene expression profile and the exacerbated asthma gene expression profile is at least one of SEQ ID NOS: 21, 37-38, 71, 85, 87, 95, 131, 147, 150-151, 154, or 166, and the difference indicates a propensity for stable asthma.
7. The method of claim 1 wherein the patient is a child.
8. A diagnostic method comprising
subjecting a nasal respiratory epithelium sample of a patient to gene analysis to obtain a tissue expression profile, and
diagnosing exacerbated asthma in the patient if at least a two-fold increase between at least one of SEQ ID NOS: 14-18, 20, 22-24, 26-36, 39-45, 47-62, 65, 67, 69-70, 72-79, 83-84, 86, 88, 90, 92-94, 96-98, 101, 105-107, 109-110, 112, 114, 117, 120, 126, 129, 132, 134-135, 139, 145-146, 152-153, 160, or 163 in the patient tissue expression profile over a control tissue expression profile is present.
9. A diagnostic method comprising
subjecting a nasal respiratory epithelium sample of a patient to gene analysis to obtain a tissue expression profile, and
diagnosing exacerbated asthma in the patient if at least a two-fold decrease in a at least one of SEQ ID NO: 11-13, 46, 63, 66, 68, 80-82, 89, 91, 99-100, 103-104, 108, 111, 115-116, 118-119, 121-125, 127-128, 130, 133, 136-138, 140-144, 148-149, 155-159, 161-162, 164-165, or 167 in the patient tissue expression profile over a control tissue expression profile is present.
10. A diagnostic method comprising
subjecting a nasal respiratory epithelium sample of a patient to gene analysis to obtain a tissue expression profile, and
diagnosing stable asthma in the patient if at least a two-fold increase between at least one of SEQ ID NOS: 15-16, 18, 28, 31, 35, 37-38, 48, 58, 72, 76-77, 101, 123, 126, 131-132, 146, 152, or 154 in the patient tissue expression profile over a control tissue expression profile is present.
11. A diagnostic method comprising
subjecting a nasal respiratory epithelium sample of a patient to gene analysis to obtain a tissue expression profile, and
diagnosing stable asthma in the patient if at least a two-fold decrease in at least one of SEQ ID NOS: 21, 29, 51, 71, 85, 87, 95, 145, 147, 150-151, or 166 in the patient tissue expression profile over a control tissue expression profile is present.
12. The method of any one of claim 8 , 9 , 10 , or 11 further comprising identifying at least one gene for prophylactic or therapeutic intervention.